The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
Enrico Costa(Brigham and Women's Hospital), Marco Cipolli(Azienda Ospedaliera Universitaria Integrata Verona), Silvia Girotti(University of Verona), Francesca Pauro(Azienda Ospedaliera Universitaria Integrata Verona), Hubert G. M. Leufkens(Utrecht University)
Cited by 51
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications
|European Journal of Clinical Pharmacology|2014|162
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
Antibiotic prescribing for children in primary care and adherence to treatment guidelines
|Journal of Antimicrobial Chemotherapy|2016|74